VECTIBIX 20 MGML Israel - English - Ministry of Health

vectibix 20 mgml

amgen europe b.v. - panitumumab - concentrate for solution for infusion - panitumumab 20 mg / 1 ml - panitumumab - in combination with chemotherapy for the treatment of unresectable, advanced or recurrent colorectal cancer (mcrc) with wild-type ras.monotherapy for the treatment of patients with metastatic colorectal carcinoma with wild-type ras after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Vectibix Concentrate for Solution for Infusion 100 mgvial Singapore - English - HSA (Health Sciences Authority)

vectibix concentrate for solution for infusion 100 mgvial

amgen biotechnology singapore pte ltd - panitumumab - infusion, solution concentrate - 100 mg/vial - panitumumab 100 mg/vial

Vectibix European Union - English - EMA (European Medicines Agency)

vectibix

amgen europe b.v. - panitumumab - colorectal neoplasms - antineoplastic agents - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri., in second-line in combination with folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan)., as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.